Veriti Management LLC bought a new stake in shares of Teladoc Health, Inc. (NYSE:TDOC – Get Rating) in the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 3,655 shares of the health services provider’s stock, valued at approximately $264,000.
A number of other institutional investors and hedge funds have also recently made changes to their positions in TDOC. Future Financial Wealth Managment LLC acquired a new stake in Teladoc Health in the fourth quarter worth about $29,000. CarsonAllaria Wealth Management Ltd. acquired a new stake in Teladoc Health in the 4th quarter worth approximately $30,000. City State Bank purchased a new stake in Teladoc Health during the 4th quarter worth approximately $27,000. Amplius Wealth Advisors LLC acquired a new position in Teladoc Health during the 4th quarter valued at approximately $38,000. Finally, Ellevest Inc. raised its holdings in shares of Teladoc Health by 133.0% in the fourth quarter. Ellevest Inc. now owns 445 shares of the health services provider’s stock worth $41,000 after buying an additional 254 shares during the last quarter. Institutional investors own 87.17% of the company’s stock.
Shares of NYSE TDOC opened at $37.17 on Monday. The company has a market capitalization of $5.99 billion, a P/E ratio of -0.86 and a beta of 0.81. The company has a debt-to-equity ratio of 0.17, a current ratio of 3.94 and a quick ratio of 3.71. The company has a 50 day simple moving average of $37.40 and a 200-day simple moving average of $61.97. Teladoc Health, Inc. has a 1 year low of $27.38 and a 1 year high of $174.32.
Teladoc Health (NYSE:TDOC – Get Rating) last issued its quarterly earnings data on Wednesday, April 27th. The health services provider reported ($0.47) earnings per share for the quarter, topping the consensus estimate of ($0.55) by $0.08. Teladoc Health had a negative return on equity of 2.12% and a negative net margin of 321.94%. The company had revenue of $565.35 million during the quarter, compared to analyst estimates of $568.91 million. During the same period in the prior year, the business posted $0.13 earnings per share. As a group, research analysts expect that Teladoc Health, Inc. will post -2.05 EPS for the current year.
In related news, SVP Daniel Trencher sold 1,000 shares of the business’s stock in a transaction dated Friday, June 17th. The shares were sold at an average price of $29.12, for a total value of $29,120.00. Following the sale, the senior vice president now directly owns 28,408 shares in the company, valued at approximately $827,240.96. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. 1.55% of the stock is currently owned by company insiders.
Several equities analysts recently issued reports on TDOC shares. Wells Fargo & Company downgraded Teladoc Health from an “overweight” rating to an “equal weight” rating and cut their target price for the company from $104.00 to $40.00 in a research report on Thursday, April 28th. William Blair cut Teladoc Health from an “outperform” rating to a “market perform” rating in a research note on Thursday, April 28th. Canaccord Genuity Group decreased their target price on Teladoc Health from $112.00 to $50.00 in a report on Thursday, April 28th. Credit Suisse Group downgraded shares of Teladoc Health from an “outperform” rating to a “neutral” rating and cut their price target for the stock from $114.00 to $35.00 in a report on Thursday, April 28th. Finally, Citigroup cut shares of Teladoc Health from a “buy” rating to a “neutral” rating and decreased their price objective for the company from $115.00 to $43.00 in a research note on Thursday, April 28th. One investment analyst has rated the stock with a sell rating, eighteen have assigned a hold rating and nine have issued a buy rating to the company. According to MarketBeat.com, Teladoc Health presently has a consensus rating of “Hold” and a consensus target price of $88.36.
Teladoc Health Profile (Get Rating)
Teladoc Health, Inc provides virtual healthcare services in the United States and internationally. The company offers a portfolio of services and solutions covering non-urgent, episodic, chronic, and complicated medical conditions, including diabetes, hypertension, chronic kidney disease, cancer, congestive heart failure, and mental health conditions.
Recommended Stories
Want to see what other hedge funds are holding TDOC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Teladoc Health, Inc. (NYSE:TDOC – Get Rating).
Receive News & Ratings for Teladoc Health Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Teladoc Health and related companies with MarketBeat.com’s FREE daily email newsletter.
Source: defenseworld.net